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Abstract
Background & Aims
We previously demonstrated that short-term oral administration of the probiotic Lactobacil-
lus reuteri 6475 enhanced bone density in male but not female mice. We also established
that L. reuteri 6475 enhanced bone health and prevented bone loss in estrogen-deficient
female mice. In this study, we tested whether a mild inflammatory state and/or a long-term
treatment with the probiotic was required to promote a positive bone effect in estrogen-suffi-
cient female mice.
Methods
Amild inflammatory state was induced in female mice by dorsal surgical incision (DSI). Fol-
lowing DSI animals were orally supplemented with L. reuteri or vehicle control for a period of
8 weeks. Gene expression was measured in the intestine and bone marrow by qPCR. Distal
femoral bone density and architecture was analyzed by micro-CT.
Results
We report that 8 weeks after DSI there is a significant increase in the weight of spleen, thy-
mus and visceral (retroperitoneal) fat pads. Expression of intestinal cytokines and tight junc-
tion proteins are also altered 8 weeks post-DSI. Interestingly, L. reuteri treatment was found
to display both intestinal region- and inflammation-dependent effects. Unexpectedly we
identified that 1) L. reuteri treatment increased bone density in females but only in those that
underwent DSI and 2) DSI benefited cortical bone parameters. In the bone marrow, dorsal
surgery induced CD4+ T cell numbers, a response that was unaffected by L. reuteri treat-
ment, whereas expression of RANKL, OPG and IL-10 were significantly affected by L. reu-
teri treatment.
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Conclusion
Our data reveals a previously unappreciated effect of a mild surgical procedure causing a
long-lasting effect on inflammatory gene expression in the gut and the bone. Additionally,
we demonstrate that in intact female mice, the beneficial effect of L. reuteri on bone requires
an elevated inflammatory status.
Introduction
Throughout life the adult human skeleton is continuously remodeled with approximately
5–10% of the existing bone replaced every year [1]. Remodeling is accomplished through the
coupled activities of osteoclasts, cells responsible for the degradation of bone, and osteoblasts,
cells that produce organic bone matrix and promote its mineralization [2,3]. The balanced pro-
cess of bone remodeling is negatively influenced by numerous factors. Up-regulated expression
of pro-inflammatory and pro-osteoclastogenic cytokines, such as tumor necrosis factor (TNF),
interleukin (IL)-1β, interferon gamma (IFNγ) and receptor activator of nuclear factor-kappa B
ligand (RANKL), have been shown to disrupt bone remodeling and lead to bone loss [4–7]. In
contrast, increased levels of the anti-osteoclastogenic cytokine osteoprotegerin (OPG) or the
anti-inflammatory cytokine IL-10 increase bone density by directly inhibiting osteoclast forma-
tion or inhibiting production of pro-inflammatory cytokines [8–10]. Consistent with a role for
local inflammation in bone density regulation, rheumatoid arthritis (RA), periodontitis, loos-
ened joint prostheses and tooth implants, all increase inflammation in close proximity to bone
and can cause local increases in RANKL and pro-inflammatory cytokines, leading to bone loss
[11]. In addition, chronic diseases associated with systemic inflammation (marked by elevated
serum cytokine levels) can also promote bone loss that is distant from the site of initiation of
inflammation as seen in periodontitis; in autoimmune diseases such as psoriasis, type 1 diabe-
tes, RA and inflammatory bowel disease (IBD) [11–14]; as well as in aging [15].
In recent years, the intestinal microbiota has emerged as a potentially important regulator
of systemic health. Dysbiosis of the intestinal microbiota is linked to the pathogenesis of a
number of diseases including diabetes, obesity, IBD, RA and liver disease which are also associ-
ated with adverse bone pathology [16–22]. Studies have demonstrated that modulation of the
microbiota with probiotic bacteria is able to reduce disease processes and a few studies, includ-
ing studies from our lab, further establish that probiotics can prevent bone pathology compli-
cations [23–25]. Additionally, our studies have also highlighted the beneficial effect of
probiotic supplementation on general bone health under non-diseased conditions [26]. In
these studies, we found that the effect of L. reuteri on bone is gender-dependent. In particular,
we demonstrated that 4-week supplementation with L. reuteri 6475 increased bone density in
male but not female mice [26]. We later demonstrated that estrogen deficient female mice
(ovariectomized model) respond to oral L. reuteri 6475 administration and display bone health
benefits. Specifically, treatment with probiotic bacteria protected against estrogen deficiency-
induced trabecular and cortical bone loss [23,24]. Given that estrogen is known to be an impor-
tant immunomodulator, it was not entirely surprising that some aspects of immune compo-
nents were altered in the ovariectomized mice. Immune responses have previously been shown
to differ between males and females. For example, in models of sepsis females withH. hepati-
cus-induced colitis and lipopolysaccharide (LPS)-induced airway inflammation display
reduced immune response and/or increased survival compared to males [27–29]. Taken
together, this suggests that estrogen can lower baseline inflammatory status and modulate
immune responses to insult.
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The studies noted above made us question if a minor surgical procedure could induce inflam-
mation and affect responses to L. reuteri treatment, especially under estrogen sufficient condi-
tions in females. We utilized dorsal surgical incision (DSI), a procedure commonly used in
ovariectomy and shammouse surgery studies that represents a precise, reproducible cut in the
skin. Remarkably, we report that DSI in female mice induces several inflammatory components
observed as long as 8 weeks after the procedure. Interestingly, while L. reuteri has no effect on
intact female mice (consistent with previous observations [26]), it increased femoral trabecular
bone density in those that had undergone DSI. Our findings suggest that in the presence of estro-
gen, a mild inflammatory status is required for L. reuteri to exert a beneficial effect on the bone.
Materials and Methods
Animals and Experimental Design
Female Balb/c mice 11 weeks of age were obtained from The Jackson Laboratory (Bar Harbour,
Maine). Mice were allowed to acclimate to animal facility for 1 week prior to start of experi-
ment. After 1 week mice were randomly split into four groups (9–18 per group): control (+/-
probiotic) or dorsal surgical incision (+/- probiotic). DSI entailed placing mice under isofluor-
ane anesthesia for< 5 minutes and making a 2 cm lower-mid dorsal incision extending
through the skin and muscle layer and then using surgical staples to close the site. Two days
after surgery mice were treated by gavaging with 300 μl (1x109 cfu/ml) L. reuteri 6475 or MRS
broth (vehicle control), three times per week for 4 or 8 weeks. L. reuteri was additionally added
to the drinking water (of L. reuteri treated groups only) at a concentration of 3.3x108 cfu/ml.
Mice were given Teklad 2019 chow (Madison, WI) and water ad libitum and were maintained
on a 12 h light/dark cycle. All animal procedures were approved by the Michigan State Univer-
sity Institutional Animal Care and Use Committee and conformed to NIH guidelines.
Bacterial Culture Conditions
L. reuteri ATCC PTA 6475 was initially cultured on deMan, Rogosa, Sharpe media (MRS, Difco)—
agar plates and kept under anaerobic conditions at 37°C for a maximum of 1 week. For gavaging of
all mice, one colony of L. reuteriwas picked and anaerobically cultured in 10ml of MRS broth for
16-18h at 37°C. MRS broth was additionally used as a negative control. For drinking water, L. reu-
teriwas anaerobically cultured in 10 ml of MRS broth for 16-18h at 37°C. The following day, the
overnight culture was sub-cultured into freshMRS and grown until log phase (OD600 = 0.4). L. reu-
teriwas spun down, re-suspended in sterile PBS, cfu/ml calculated and stored at -80°C until use. L.
reuteriwas re-suspended in drinking water at a final concentration of 3.3x108 cfu/ml.
μCT Bone Imaging
Fixed femurs were scanned using a GE Explore Locus microcomputed tomography (μCT) sys-
tem at a voxel resolution of 20μm obtained from 720 views. Beam angle of increment was 0.5,
and beam strength was set at 80 peak kV and 450 uA. Each run consisted of control (non-sur-
gery and DSI) and L. reuteri- treated mouse bones, and a calibration phantom to standardize
grayscale values and maintain consistency. Bone measurements were performed blind. Femoral
bone analyses were performed in a region of trabecular bone defined at 1% of the total length
proximal to the growth plate and extending 2 mm toward the diaphysis excluding the outer
cortical bone. Trabecular bone mineral content, bone volume fraction, thickness, spacing, and
number values were computed by a GE Healthcare MicroView software application for visuali-
zation and analysis of volumetric image data. Cortical measurements were performed in a
2x2x2 mm cube centered midway down the length of the bone.
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Femoral Dynamic Measures
For dynamic histomorphometric measures of bone formation, mice were injected intraperito-
neally with 200 μl of 10 mg/ml calcein (Sigma, St. Louis, MO) dissolved in sterile saline at 7
and 2 days prior to harvest. Femora (n = 8–12 per group) were embedded in paraffin blocks
sectioned, viewed under a fluorescent microscope and digital images obtained. The distance
between the calcein lines (mineral apposition rate, MAR) and their length along the bone sur-
face were measured and used to calculate bone formation rate (BFR).
Flow Cytometric Analysis
Following euthanasia femora were cleaned of muscle and bone marrow (BM) cells isolated by
either flushing or spinning (n = 10–18 per group). 1x106 cells were incubated with Fc block
(BD Pharmingen, CA, USA) for 15 min. Cells were stained with anti-mouse CD3-AlexaFluor
700 (500A2, eBioscience), anti-mouse CD4-FITC (RM 4–5, eBioscience) and anti-mouse
CD8a-PE-Cyanine5.5 (5–6.7, eBioscience) for 30 minutes before fixing in formaldehyde. Data
were acquired on a BD LSRII (Becton Dickinson, Franklin Lakes, NJ) and analyzed with FlowJo
(Version 10; FlowJo, LLC, Ashland OR).
Bone Marrow and Intestine RNA Analysis
Bone marrow was obtained as described above. Immediately following euthanasia, intestines
were cleaned of connective tissue and luminal contents, snap frozen in liquid nitrogen and
stored at -80°C. Frozen intestines were crushed under liquid nitrogen conditions with a Bess-
man Tissue Pulverizer (Spectrum Laboratories, Rancho Dominguez, CA). RNA was isolated
from frozen samples (n = 6–10 per group) using TriReagent (Molecular Research Center, Cin-
cinnati, OH) and integrity assessed by formaldehyde-agarose gel electrophoresis. cDNA was
synthesized by reverse transcription using Superscript II Reverse Transcriptase Kit and oligo
dT(12–18) primers (Invitrogen, Carlsbad, CA). cDNA was amplified by quantitative PCR
(qPCR) with iQ SYBR Green Supermix (BioRad, Hercules, CA), and gene specific primers
(synthesized by Integrated DNA Technologies, Coralville, IA; Table 1). Hypoxanthine guanine
phosphoribosyl transferase (HPRT) mRNA levels were used as an internal control.
Real time PCR was carried out for 40 cycles using the iCycler (Bio-Rad) and data evaluated
using the iCycler software. Each cycle consisted of 95°C for 15 sec, 60°C for 30 sec and 72°C for
30 sec. Negative controls included primers without cDNA.
SerumMeasurements
Blood was collected at the time of harvest, allowed to clot at room temperature for 5 min, then
centrifuged at 5000g for 10 min. Serum was removed, aliquoted and frozen in liquid nitrogen,
Table 1. qPCR Primers.
Gene Forward (5’-3’) Reverse (5’-3’)
HPRT AAGCCTAAGATG AGCGCAAG TTACTAGGCAGATGGCCACA
OPG TGGAGATCGAATTCTGCTTG TCAAGTGCTTGAGGGCATAC
RANKL TTTGCAGGACTCGACTCTGGAG TCCCTCCTTTCATCAGGTTATGAG
IL-10 GGTTGCCAAGCCTTATCGGA ACCTGCTCCACTGCCTTGCT
TGFβ1 GCAACAATTCCTGGCGTTACC CCCTGTATTCCGTCTCCTTGGT
TNF AAGGGAGAGTGGTCAGGTTGCC CCTCAGGGAAGAGTCTGGAAAGG
IFNγ GGCTGTCCCTGAAAGAAAGC GAGCGAGTTATTTGTCATTCGG
IL-1β TCCCCGTCCCTATCGACAAAC GCGGTGATGTGGCATTTTCTG
Occludin GCTCAGGGAATATCCACCTAT CACAAAGTTTTAACTTCCCAGACG
doi:10.1371/journal.pone.0153180.t001
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and stored at -80°C. Serum tartrate resistant acid phosphatase 5b (TRAP5b) and Osteocalcin
(OC) were measured using Mouse TRAP (SB-TR103, Immunodiagnostic Systems Inc., Foun-
tain Hills, AZ) and OC assay kits (BT-470, Biomedical Technologies Inc., Stoughton, MA),
respectively, according to the manufacturer’s protocol (n = 7–18 per group).
Statistical Analysis
All measurements are presented as the mean ± SEM. Significant outliers were removed using
the Grubb’s test for outliers. 1-way ANOVA was performed using GraphPad Prism software
version 6 (GraphPad, San Diego, CA, USA). A p-value0.05 was considered significant.
Results
Effect of Dorsal Surgical Incision (DSI) and L. reuteri on General Body
Parameters
Previous studies demonstrated that supplementation with L. reuteri for 4 weeks significantly
increased femoral bone density in specific-pathogen free male mice and prevented ovariec-
tomy-induced bone loss in female mice. However, 4 weeks of L. reuteri treatment failed to have
a significant effect on bone density in intact female mice [23,26]. Therefore, we investigated
whether long-term (8 weeks) L. reuteri supplementation could modulate bone density in intact
female mice and also tested whether an underlying inflammatory condition was required to
obtain a beneficial bone response. Intact mice and mice that underwent DSI were given either
L. reuteri 6475 or MRS broth (vehicle) orally by drinking water and by gavage 3x a week for the
duration of the study. Mice were sacrificed at the end of the study and general body parameters
measured (Fig 1). Interestingly, DSI mice (± L. reuteri) displayed significantly increased weight
of spleen (p<0.001), thymus (p<0.001) and retroperitoneal fat (p<0.01) when compared to
non-surgery mice 8 weeks post-surgery. DSI and L. reuteri had no significant effects on body
mass and inguinal fat mass compared to the respective controls.
Assessing the Impact of DSI and L. reuteri on Trabecular Bone Volume
Fraction and Cortical Bone
To assess whether long-term L. reuteri supplementation benefits bone health, we examined the
distal femur metaphyseal trabecular region by microcomputed tomography 8 weeks after the
start of treatment (Table 2). Remarkably, we identified a significant increase (nearly 50%) in
bone volume fraction (BVF; Fig 2) in the DSI + L. reuteri cohort compared to the DSI + broth
group (p<0.05) and non-surgery control (p<0.05). Consistent with this finding, trabecular
number (Tb. N, p<0.05) increased and trabecular spacing (Tb. Sp.) decreased (p<0.05) in the
L. reuteri treated DSI cohort compared to the non-surgery control (Table 2). In contrast, we
did not observe any change in BVF in the non-surgery + L. reuterimice compared to the non-
surgery controls, consistent with previous observations [26]. Analysis of femoral diaphysis cor-
tical parameters (Table 2) revealed that DSI had a major effect on the cortical bone structure
and strength. Specifically, DSI significantly increased inner perimeter (p<0.01), outer perime-
ter (p<0.01), marrow area (p<0.05), cortical area (p<0.05), total area (p<0.0001), bone min-
eral content (p<0.05) and moment of inertia (p<0.01) when compared to the non-surgery
control. L. reuteri had no effect on cortical parameters in either the non-surgery or DSI treated
cohorts.
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Long-term Effects of DSI and L. reuteri on Intestinal Cytokine Gene
Expression
Knowing that DSI has systemic effects on bone, we wondered if DSI also affected the GI tract,
contributing to the bone changes induced by surgery and L. reuteri supplementation. To test
this hypothesis, we examined genes associated with gut-bone signaling pathways: jejunal and
colonic gene expression of markers of inflammation (pro- and anti-inflammatory cytokines)
and genes involved in gut barrier function (occludin) (Fig 3) which have been suggested to be
involved in bone density regulation [30].
In the jejunum, DSI promoted inflammation as indicated by significant increases in gene
expression of TNFα (p<0.001), IL-1β (p<0.01), TGFβ (p<0.001), IFNγ (p<0.05) and
Fig 1. DSI Increases General Markers of Inflammation. a) Body Mass, b) spleen c) thymus d)
retroperitoneal fat and e) inguinal fat were weighed after an 8 week period in non-surgery and DSI mice ± L.
reuteri. DSI significantly increased spleen weight (p<0.0001), thymus weight (p<0.0001) and retroperitoneal
fat (p<0.001) but had no significant effect on body mass or inguinal fat. n = 9–18 per group. Data is
mean ± SEM. Statistical analysis performed by 1-way ANOVA with Fisher’s LSD post-test.
doi:10.1371/journal.pone.0153180.g001
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significantly decreased expression of IL-10 (p<0.01) and occludin (p<0.01). This was consis-
tent with our hypothesis of DSI altering gut homeostasis, even 8 weeks after surgery. Even
more interesting, some of these changes induced by DSI were reversed by L. reuteri treatment:
expression of TNFα (p<0.0001), IFNγ (p<0.001) and TGFβ (p<0.0001) were decreased while
occludin expression was increased in L. reuteri treated DSI group. Supplementation of the
non-surgery cohort with L. reuteri significantly decreased expression of IL-10 (p<0.01). This
was interesting even though intact females do not exhibit any bone effect following L. reuteri
supplementation.
Compared to the jejunum, colonic TNFα significantly increased (p<0.05) while IL-10 trended
upwards 8 weeks post-DSI. As in the jejunum, expression of occludin (p<0.01), and TGFβ
(p<0.05) were significantly decreased in DSI mice. Unexpectedly, L. reuteri supplementation of
the DSI group caused significant increases in expression of TNFα (p<0.01, 4-fold), IL-1β
(p<0.01, 4-fold) and increased IL-10 (3-fold) compared to treated non-surgery mice. These
increases were much greater than what was seen in the jejunum. In contrast, and more consistent
with previous studies, L. reuteri treatment of intact female mice led to a significant decrease in
occludin (p<0.01), IL-1β (p<0.05) and TGFβ (p<0.01) expression in the non-surgery cohort.
Together, these results suggest that L. reuteri differentially affects intestinal gene expression
depending on the intestinal segment and on presence or absence of a distant surgical stress.
Modulation of the Bone Marrow CD4+ T Cell Population by DSI and L.
reuteri
To determine whether DSI and/or oral L. reuteri administration could lead to a bone marrow
(BM) cellular composition that is associated with changes in bone density, we analyzed BM
CD4+ T cell numbers by flow cytometry at 8 weeks (Fig 4). BM CD4+ T cells have been shown
to be important regulators of bone health [31]. Eight weeks following DSI, we identified a
Table 2. Femoral and Cortical Bone Parameters.
Femur Trabecular Bone Parameters Non-Surgery DSI Non-Surgery+ L. reuteri DSI+ L. reuteri
% BVF 22.4±2.1 24.1±1.7 20.9±2.8 31.4±2.3*
Tb. N. (1/mm) 4.44±0.31 5.18±0.23 4.26±.030 5.63±0.37*
Tb. Th. (μm) 48±2 45±2 47±3 50±2
Tb. Sp. (mm) 0.19±0.01 0.15±0.01 0.20±0.02 0.13±0.01*
BFR(μm) 1.80±0.31 2.82±0.36 2.03±0.50 2.95±0.44
MAR (μm/day) 0.26±0.02 0.50±0.09* 0.39±0.10 0.62±0.16*
Femoral Cortical Bone Parameters Non-Surgery DSI Non-Surgery+ L. reuteri DSI+ L. reuteri
Inner Perimeter (mm) 2.65±0.04 2.81±0.04** 2.71±0.02 2.83±0.04**
Outer Perimeter (mm) 4.22±0.05 4.46±0.04** 4.29±0.03 4.54±0.05**
Marrow Area (mm2) 0.48±0.01 0.55±0.02** 0.51±0.01 0.56±0.02
Cortical Area (mm2) 0.84±0.02 0.93±0.02** 0.87±0.01 0.98±0.03**
Total Area (mm2) 1.32±0.03 1.48±0.02** 1.38±0.02 1.54±0.03**
BMD (mg/cc) 857±17 905±32 844±10 821±32
BMC (μg) 14.5±0.5 16.9±0.5** 14.7±0.3 16.2±0.8*
MOI (mm4) 0.24±0.01 0.30±0.01** 0.26±0.01 0.33±0.01**
Femur distal trabecular bone parameters. % BVF, bone volume fraction; Tb. N., trabecular number; Tb. Th., trabecular thickness; Tb. Sp., trabecular
spacing; MAR, mineral apposition rate; BFR, bone formation rate; MOI, the cross sectional moment of inertia at the z-axis. Values are averages ± SEM.
N = 7–18 per group. * Signiﬁcant compared to non-surgery control
* p<0.05
** p<0.01. Statistical analysis performed with 1 Way ANOVA followed by or Fisher’s LSD post-test.
doi:10.1371/journal.pone.0153180.t002
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significant increase in the percentage of BM CD4+ T cells in the DSI group (17.7±1.1%) com-
pared to the non-surgery cohort (6.8±0.7%; p<0.0001). L. reuteri treatment had no effect on
CD4+ T cell numbers. No significant difference was observed in CD8+ T cell numbers between
any of the conditions. These results suggest that the L. reuteri effect on bone density in the DSI
group is likely independent of CD4+ T cell changes in the BM.
Analysis of Osteoblast/Osteoclast Bone Remodeling Markers
To determine whether L. reuteri supplementation decreased catabolic and/or increased ana-
bolic bone responses, markers of osteoclast and osteoblast activity were measured in bone, BM
and serum at 8 weeks. Serum levels of osteocalcin were significantly increased in the DSI cohort
Fig 2. L. reuteri Significantly Increases Bone Volume in Female Mice 8Weeks after DSI. Non-surgery
and DSI mice were treated ± L. reuteri for 8 weeks and trabecular bone density analyzed by μCT. i) L. reuteri
significantly increased %BVF in the DSI mice compared to DSI control (p<0.05) and non-surgery control
(p<0.05). No significant difference was observed between the non-surgery and DSI controls. L. reuteri had no
effect in the non-surgery cohort. Representative μCT isosurface images of ii) DSI and iii) DSI + L. reuteri.
n = 8–18 per group. Statistical analysis performed by 1-way ANOVAwith Fisher’s LSD post-test.
doi:10.1371/journal.pone.0153180.g002
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(2.1-fold-170.7 ± 8.5 ng/ml, p<0.01) compared to the non-surgery controls (81.1 ± 20.6 ng/ml;
Fig 5). TRAP5b levels, a specific marker of osteoclast activity, were modestly increased in the
DSI group (4.0 ± 0.2 U/L) compared to non-surgery controls (3.3 ± 0.5 U/L). L. reuteri treat-
ment had no significant effect on serum TRAP5b and osteocalcin levels in either the non-sur-
gery or DSI groups. Consistent with the serum osteocalcin levels, analysis of calcein
incorporation, a dynamic measure of bone formation, identified an increase in mineral apposi-
tion rate in the DSI mice (0.50 ± 0.09μm/day) and DSI + L. reuterimice (0.62 ± 0.16μm/day;
p<0.05) compared to the non-surgery controls (0.26 ± 0.02 μm/day) (Fig 4). Consistent with
the changes in MAR, BFR trended to be higher in the DSI cohorts compared to the non-surgery
controls, though this increase was not significant (Table 2). To further assess the effect of DSI
and/or L. reuteri on BM, we examined the expression of the osteoclastogenic cytokine RANKL,
the anti-osteoclastogenic cytokine OPG and the anti-inflammatory cytokine IL-10 (Fig 5).
Eight weeks post-surgery, expression of RANKL and OPG were increased in the DSI group
compared to the non-surgery group (4.3- and 10.2-fold respectively). This resulted in an
increase in the OPG:RANKL ratio in the DSI control group compared to the non-surgery con-
trols. In addition, IL-10 expression was enhanced in the DSI controls compared to the non-sur-
gery controls. None of these parameters were affected significantly by L. reuteri treatment in
the DSI group. Because of the observed bone effects at 8-weeks post-surgery/treatment, we rea-
soned that gene expression changes may have occurred earlier in the process. Therefore, we
examined expression of the above-described genes in the BM from mice that underwent DSI ±
L. reuteri 4 weeks after surgery. As posited, at 4 weeks, L. reuteri caused a significant reduction
Fig 3. DSI and L. reuteri Significantly Alter Regional Intestinal Gene Expression. Non-surgery and DSI
mice were treated ± L. reuteri for 8 weeks and gene expression analyzed in the jejunum and colon by qPCR.
In the jejunum DSI significantly increased expression of TNFα (p<0.001), IL-1β (p<0.01), IFNγ (p<0.05) and
TGFβ (p<0.001). Significant decreases in IL-10 (p<0.01) and occludin (p<0.01) were observed. In the non-
surgery cohort L. reuteri significantly reduced IL-10 (p<0.01) expression. In the DSI cohort significant
reductions were observed for TNFα (p<0.0001), IFNγ (p<0.001) and TGFβ (p<0.0001). In the colon, DSI
resulted in a significant increase in TNFα (p<0.05) and a decrease in occludin expression (p<0.05). L. reuteri
significantly reduced expression of occludin (p<0.05), IL-1β (p<0.05) and TGFβ (p<0.01) in the non-surgery
cohort. In the DSI cohort, L. reuteri significantly increased expression of TNFα (p<0.01) and IL-1β (p<0.01)
while increasing expression of IL-10. n = 8–10 per group. * = significant to non-surgery control, ^ = significant
to DSI control. Statistical analysis performed by 1-way ANOVAwith Fisher’s LSD post-test.
doi:10.1371/journal.pone.0153180.g003
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Fig 4. DSI Increases CD4+ T Cell Numbers in Bone Marrow and Significantly Increases Markers of
Osteoblast Bone Formation after 8 Weeks. Non-surgery and DSI mice were treated ± L. reuteri for 8
weeks. Bone marrow was isolated and CD4+ T cell numbers analyzed by flow cytometry and osteoclast and
osteoblast bone remodeling markers analyzed. a) Representative flow cytometry scatter plots. CD4+ T cells
numbers were significantly increased in DSI mice (p<0.0001) compared to the non-surgery cohort. L. reuteri
had no significant effect on CD4+ T cell numbers. b) MAR was measured by calcein incorporation, DSI + L.
reuteri significantly increased MAR compared to non-surgery controls (p<0.05). Representative fluorescent
images of calcein incorporation are included on the right. c, d) DSI had no effect on serum TRAP5b (c) but
significantly increased levels of serum osteocalcin (d) compared to the non-surgery control (p<0.01). L.
reuteri had no effect on TRAP5b or osteocalcin levels. n = 7–18 per group. * = significant to non-surgery
control, ^ = significant to DSI control. Data is mean ± SEM. Statistical analysis performed by 1-way ANOVA
with Tukey post-test or Fisher’s LSD test.
doi:10.1371/journal.pone.0153180.g004
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Fig 5. DSI and L. reuteriAlter BoneMarrow Gene Expression at 4 and 8Weeks. Bone marrow was
isolated from 4 and 8 week Non-surgery and DSI mice ± L. reuteri and gene expression analyzed by qPCR.
At 4 weeks L. reuteri significantly reduced RANKL expression in the DSI cohort (p<0.05). L. reuteri
additionally increased OPG expression resulting in a significant increase in the OPG:RANKL ratio (p<0.05)
compared to the DSI control. At 8 weeks RANKL and OPG expression trended higher in the DSI control
compared to the non-surgery control, resulting in an increased OPG:RANKL ratio. IL-10 expression was
elevated in the DSI control over the non-surgery control. In the non-surgery cohort L. reuteri increased OPG
and IL-10 expression. In the DSI cohort, L. reuteri decreased RANKL while increasing OPG expression
resulting in a trend towards an increased OPG:RANKL ratio. n = 6–10 per group. * = significant to non-
surgery control, ^ = significant to DSI control. Statistical analysis performed by 1-way ANOVA with Fisher’s
LSD test.
doi:10.1371/journal.pone.0153180.g005
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(2.4-fold) in RANKL gene expression (p<0.05) and 1.8 fold increase in OPG expression. Anal-
ysis of the OPG:RANKL ratio revealed a significant elevation (2.4-fold) in the DSI + L. reuteri
cohort when compared to the DSI mice (p<0.05). L. reuteri had no effect on BM IL-10 expres-
sion at 4 weeks. Together, these studies suggest that L. reuteri likely modulates genes responsi-
ble for bone remodeling in the BM. Whether these effects are consequences of intestinal
changes or direct effect of L. reuteri secretory products will be the focus of future studies.
Discussion
Recent studies have revealed a positive effect of probiotic supplementation on bone health in
intact male mice and in estrogen-deficient female mice [23,24,26]. In contrast however, supple-
mentation in intact female mice displayed no bone effect [26]. In the present study we reveal
that dorsal skin incision (DSI) has long-lasting systemic effects on inflammatory status, and
that treatment with the probiotic bacterium L. reuteri 6475 exerts a beneficial bone effect in
female DSI mice in addition to modulating the expression of pro-inflammatory and pro-osteo-
clastogenic cytokines in the intestine and bone marrow.
Under normal physiological conditions inflammation is a controlled adaptive response by
the body consequent to injury or infection, returning it to homeostasis. Dysregulation of this
inflammatory process can lead to adverse pathology such as that seen in IBD, RA, estrogen
deficiency and obesity [16–19,32]. Inflammatory cytokines can promote osteoclast bone
resorption and bone loss. Previous studies investigating the effect of L. reuteri on bone health
utilized intact male mice and the OVX model of estrogen deficiency; both models displaying
significantly elevated markers of inflammation compared to intact female mice. In the present
study, a model of non-pathological inflammation was required for L. reuteri to exhibit a bone
effect in female mice.
Wound healing (surgery) induces a coordinated and controlled acute inflammatory
response and was chosen over other models of inflammation such as low dose LPS- or DSS-
induced inflammation, as these are closely related to pathological models of obesity and IBD
respectively [33–36]. While inflammation associated with wound healing is generally consid-
ered localized to the site of insult, the present study revealed that at 8 weeks post-dorsal skin
incision, general markers of systemic inflammation were still elevated: spleen, thymus and vis-
ceral fat weights were significantly increased. In addition, expression of pro-inflammatory
genes, TNFα, IL-1β and IFNγ were elevated in the intestine. These markers indicated that the
DSI mice, while visibly healed and showing no overt signs of illness or distress, were experienc-
ing a low-grade systemic inflammation compared to the non-surgery controls.
In pathological states, such as RA or IBD, high levels of inflammation have an adverse effect
on bone health. Pro- inflammatory and–osteoclastogenic cytokines such as, TNFα, IL-1β, IFNγ
and RANKL, are increased while expression of the anti-osteoclastogenic cytokine OPG is
decreased. This results in enhanced osteoclast formation and activity and suppressed osteoblast
bone formation, leading to net bone loss [28,37–39]. The effect of low-grade inflammation on
bone health however, is not as well defined. In adverse conditions such as obesity and diabetes,
which are associated with a dysregulated chronic low grade inflammation, a lower BV/TV has
been reported due to increased osteoclastogenesis and decreased osteoblast differentiation
[20,25,40–42]. In the present study, no difference in trabecular BVF was observed between the
non-surgery and the DSI mice. However, we did observe that DSI increased cortical bone
parameters, including thickness, mineral content and calculated strength. MAR and serum
osteocalcin levels were also elevated in the DSI mice, suggesting in this model that inflamma-
tion increased bone remodeling and that bone outcomes are site dependent. Specifically, sur-
gery-induced changes were targeted to cortical bone where resorption and formation are not in
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balance and lead to structural changes. Osteocytes are known to play a critical role in the main-
tenance of homeostatic bone remodeling, through the production of RANKL [43,44] and could
be involved in this process and contribute to site specific differences. We specifically examined
bone marrow changes to assess the role of immune cells in DSI and L. reuteri responses. We
identified that RANKL, OPG and IL-10 gene expression in DSI BM significantly increased
along with the number of CD4+ T cells, another known producer of RANKL [1]. The results of
these analyses support the notion that DSI increases bone remodeling that is in balance in tra-
becular bone but not in cortical bone. This effect is in contrast to what has been observed in
obesity and diabetes, where RANKL is elevated and OPG and IL-10 expression reduced
[42,45]. These observations suggest that the context of inflammation, controlled versus patho-
logic, has an important role in the outcome on bone health. Having identified that DSI induced
a controlled systemic inflammatory response in female mice that had no detrimental effect on
bone health, we demonstrate that supplementation with L. reuteri could produce the beneficial
bone effect observed in male mice and OVX female mice.
In-line with previous reports for intact and diabetic male mice, L. reuteri had no effect on
general body mass in either the non-surgery or DSI cohorts [25,26]. Consistent with previously
published bone data supporting a requirement for inflammation in the response to probiotics,
L. reuteri had an anabolic effect on bone only in the DSI cohort [23,26]. Also in line with this,
2-way ANOVA, used to examine if L. reuteri and surgery effects on mineral apposition rate
were dependent or independent, determined that L. reuteri had no significant effect on MAR
on its own. The exact mechanism through which L. reuteri increases bone density is currently
not fully understood. However, in the present study L. reuterimodulated expression of BM
RANKL, OPG and IL-10 gene expression, shifting the balance towards an anti-osteoclastogenic
environment. Interestingly, the level of modulation was dependent on the presence of inflamma-
tion with the greatest changes observed in the DSI cohort, potentially due to the increased num-
bers of CD4+ T cells present in the BM. Studies have identified that probiotic bacteria can
modulate T cell differentiation, up-regulating CD4+Foxp3+ Tregs while down-regulating Th1
and Th17 cytokine expression [46–48]. In the present study the numbers of CD4+Foxp3+ Tregs
were not measured though the increase in expression of IL-10 and decreased RANKL gene
expression suggests that L. reuteri is potentially modulating CD4+ T cell lineage selection. What
remains to be determined however, is whether L. reuteri is modulating lineage selection within or
before migration to the BM.While in the present study changes in BM gene expression were
observed in the surgery cohort at 4 weeks a previous study from our laboratory reported no
changes in bone density in sham operated mice at this time point [23]. This suggests that in
female mice, under non-pathological low-grade inflammation, long-term supplementation with
L. reuteri is required to increase bone density. The exact mechanisms of how intestinal micro-
biota affects bone health is still under investigation, though modulation of intestinal pro-inflam-
matory cytokine expression has been suggested to have an important role [26,49].
In the present study L. reuteri had regional and inflammation-dependent effects on intesti-
nal cytokine gene expression. In the DSI cohort jejunal pro-inflammatory cytokine expression
was reduced, supporting the observations in male mice by McCabe, Britton et al [26]. Interest-
ingly however, an increase in colonic pro-inflammatory cytokine expression, notably TNF, was
observed. Why L. reuteri would have region specific effects on cytokine expression in the intes-
tine is not clear from this study, though a similar effect with commensal bacteria had been
observed in gnotobiotic pigs [50]. A possible explanation for the regional difference in cytokine
response is the difference in cellular make-up of the sections of the intestine; higher numbers
and density of Peyer’s patches are found in the small intestine while equivalent M-cell contain-
ing macroscopic structures are found in the large intestine. Additionally 10- to 20-fold more
intraepithelial lymphocytes can be isolated from the small intestine compared to the colon
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[51]. This suggests L. reuteri has differential effects and highlights a complex interplay between
microbiota and host.
The L. reuteri-induced increase in intestinal pro-inflammatory cytokine expression is not
without precedent. In a study by Pagnini et al [52] the probiotic cocktail VSL#3 stimulated ileal
epithelial production of TNF. This increase in TNF was thought to protect against the onset of
intestinal inflammation in the SAMP mouse model of Crohn’s disease-ileitis via local stimula-
tion of the epithelial innate immune system, restoring epithelial barrier function. The effect of
L. reuteri on epithelial barrier function in the current study cannot be conclusively determined.
As with cytokine expression, region- and inflammation-dependent effects were apparent in
epithelial tight junction protein mRNA expression. In the jejunum, under an inflammatory set-
ting, L. reuteri increased mRNA expression of the tight junction protein occludin. In contrast,
L. reuteri led to decreased occludin expression in the colon under non-inflammatory condi-
tions. Whether these changes translate to changes in intestinal permeability however, remains
to be investigated.
Comparison of the present study to the effects of L. reuteri on male mice and the estrogen-
deficient OVX female mice raises a number of intriguing queries. Normal intact female mice
display significantly lower intestinal inflammation compared to their male counterparts
(unpublished data from our laboratory), while following estrogen deficiency inflammatory lev-
els increase [32]. This suggests a minimal level of inflammation is required for L. reuteri to
exert a beneficial bone effect. What this activating factor is however remains to be determined;
whether it’s the presence of pro-inflammatory cytokines, certain activated immune cells in or
around the intestine or some other hitherto unknown factor.
In summary, this study provides the first evidence that the probiotic bacteria L. reuteri
requires a mild inflammatory status in vivo to provide a beneficial bone effect in female mice.
We show that surgical dorsal skin incision induces a controlled systemic low -grade chronic
inflammation that increases expression of pro-inflammatory cytokines in the intestine and the
BM. We reveal that L. reuterimodulates expression of intestinal pro-inflammatory cytokines
and tight junction protein expression in a regional- and inflammation-dependent manner and
that L. reuteri can regulate BM gene expression of RANKL, OPG and IL-10. These data reveal
the complex interaction between host and microbiota and the gut–bone axis.
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